Elasmogen Team Publications

Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography

Obinna C. Ubah, Eric W. Lake, Gihan S. Gunaratne, Joseph P. Gallant, Marie Fernie, Austin J. Robertson, Jonathan S. Marchant, Tyler D. Bold, Ryan A. Langlois, William E. Matchett,Joshua M. Thiede, Ke Shi, Lulu Yin, Nicholas H. Moeller, Surajit Banerjee, Laura Ferguson,Marina Kovaleva, Andrew J. Porter, Hideki Aihara, Aaron M. LeBeau & Caroline J. Barelle
Nature Communications 2021; doi:10.1038/s41467-021-27611-y

Read now…

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M.
Nanoscale Drug, Design, development and Therapy 2021; doi: 10.2147/DDDT.S315724

Read now…

Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature

Leach A, Smyth P, Ferguson L, Steven J,Greene M, Branco C, McCann A, Porter A, Barelle C, Scott C
Nanoscale 2020 doi:10.1039/D0NR02962A.

Read now…

Isolation of highly selective IgNAR variable single-domains against a human therapeutic Fc scaffold and their application as tailor-made bioprocessing reagents

Magdalena J Buschhaus, Stefan Becker, Andrew J Porter, Caroline J Barelle
Protein Engineering Design and Selection 2020 doi:10.1093/protein/gzaa002

Read now…

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

Obinna C. Ubah, Andrew J. Porter, and Caroline J. Barelle
Journal of Immunology Research 2020; doi: 10.1155/2020/7283239

Read now…

Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand.

Kathryn L. Pepple, Leslie Wilson, Russell N. Van Gelder, Marina Kovaleva, Obinna C. Ubah, John Steven, Caroline J. Barelle, and Andrew Porter
Trans. Vis. Sci. Tech. 2019;8(5):11. doi: 10.1167/tvst.8.5.11.

Read now…

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA-PEG nanoparticles enhances nanoconjugate performance.

João C. F. Nogueira, Michelle K. Greene, Daniel A. Richards, Alexander O. Furby, John Steven, Andrew Porter, Caroline Barelle, Christopher J. Scott and Vijay Chudasama
ChemComm 2019 May. doi: 10.1039/C9CC02655J

Read now…

An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model.

Ubah Obinna C., Steven John, Porter Andrew J., Barelle Caroline J.
Frontiers in Immunology 2019 March 10:526. doi: 10.3389/fimmu.2019.00526

Read now…

Next-generation flexible formats of VNAR domains expand the drug platform’s utility and developability.

Ubah OC, Buschhaus MJ, Ferguson L, Kovaleva M, Steven J, Porter AJ, Barelle CJ.
Biochem Soc Trans. 2018 Dec 17;46(6):1559-1565. doi: 10.1042/BST20180177. Epub 2018 Oct 31. Review.

Read now…    (PubMed)

Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis.

Ronan O’Dwyer, Marina Kovaleva, Jiquan Zhang, John Steven, Emma Cummins, Deborah Luxenberg, Alfredo Darmanin-Sheehan, Miguel F. Carvalho, Matthew Whitters, Kenneth Saunders, and Caroline J. Barelle.
Journal of Immunology Research 2018 Oct ID 4089459

Read now… (PubMed)

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development.

Steven J, Müller MR, Carvalho MF, Ubah OC, Kovaleva M, Donohoe G, Baddeley T, Cornock D, Saunders K, Porter AJ, Barelle CJ.
Front Immunol. 2017 Oct 23;8:1361. doi: 10.3389/fimmu.2017.01361. eCollection 2017

Read now… (PubMed)

Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.

Ubah OC, Steven J, Kovaleva M, Ferguson L, Barelle C, Porter AJR, Barelle CJ.
Front Immunol. 2017 Oct 23;8:1780. doi: 10.3389/fimmu.2017.01780. eCollection 2017.

Read now… (PubMed)

Phage Display Derived IgNAR V Region Binding Domains for Therapeutic Development.

Ubah OC, Barelle CJ, Buschhaus MJ,Porter AJ.
Curr Pharm Des. 2016;22(43):6519-6526. doi: 10.2174/1381612822666160907091708. Review.

Read now… (PubMed)

Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis.

Marina Kovaleva, Katherine Johnson, John Steven, Caroline Barelle and Andrew Porter.
Front Immunol. 2017 Sep 25;8:1121. doi: 10.3389/fimmu.2017.01121. eCollection 2017.

Read now… (PubMed)

Structural insights and biomedical potential of IgNAR scaffolds from sharks.

Zielonka S, Empting M, Grzeschik J, Könning D, Barelle CJ, Kolmar H.
MAbs. 2015; 7(1):15-25. doi: 10.4161/19420862.2015.989032.

Read now… (PubMed)

VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins

Caroline Barelle, Andy Porter
Antibodies 2015, 4(3), 240-258; doi:10.3390/antib4030240

Read now… (Journal)

Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development.

Kovaleva M, Ferguson L, Steven J, Porter A, Barelle C.
Expert Opin Biol Ther. 2014 Oct; 14(10):1527-39. doi: 10.1517/14712598.2014.937701. Epub 2014 Aug 4.

Read now… (PubMed)

Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis.

Kovalenko OV, Olland A, Piché-Nicholas N, Godbole A, King D, Svenson K, Calabro V, Müller MR, Barelle CJ, Somers W, Gill DS, Mosyak L, Tchistiakova L.
J Biol Chem. 2013 Jun 14; 288(24):17408-19. doi: 10.1074/jbc.M112.435289. Epub 2013 Apr 30.

Read now… (PubMed)

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

Müller MR, Saunders K, Grace C, Jin M, Piche-Nicholas N, Steven J, O’Dwyer R, Wu L, Khetemenee L, Vugmeyster Y, Hickling TP, Tchistiakova L, Olland S, Gill D, Jensen A, Barelle CJ.
MAbs. 2012 Nov-Dec; 4(6):673-85. doi: 10.4161/mabs.22242.

Read now… (PubMed)

Generation and isolation of target-specific single-domain antibodies from shark immune repertoires.

Müller MR, O’Dwyer R, Kovaleva M, Rudkin F, Dooley H, Barelle CJ.
Methods Mol Biol. 2012; 907:177-94. doi: 10.1007/978-1-61779-974-7_9.

Read now… (PubMed)

Characterization of the immunoglobulin repertoire of the spiny dogfish (Squalus acanthias).

Smith LE, Crouch K, Cao W, Müller MR, Wu L, Steven J, Lee M, Liang M, Flajnik MF, Shih HH, Barelle CJ, Paulsen J, Gill DS, Dooley H.
Dev Comp Immunol. 2012 Apr; 36(4): 665-79. doi: 10.1016/j.dci.2011.10.007. Epub 2011 Oct 20.

Read now… (PubMed)

Shark novel antigen receptors–the next generation of biologic therapeutics?

Barelle C, Gill DS, Charlton K.
Adv Exp Med Biol. 2009; 655:49-62. doi: 10.1007/978-1-4419-1132-2_6.

Read now… (PubMed)